We are live on ! Find out more
BSX icon

Boston Scientific

878 hedge funds and large institutions have $48.1B invested in Boston Scientific in 2022 Q2 according to their latest regulatory filings, with 80 funds opening new positions, 326 increasing their positions, 320 reducing their positions, and 92 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 1421 (+7)

1.15% more ownership

Funds ownership: 90.11%91.26% (+1.1%)

2% more repeat investments, than reductions

Existing positions increased: 326 | Existing positions reduced: 320

0% less call options, than puts

Call options by funds: $312M | Put options by funds: $313M

3% less funds holding

Funds holding: 904878 (-26)

13% less first-time investments, than exits

New positions opened: 80 | Existing positions closed: 92

15% less capital invested

Capital invested by funds: $56.8B → $48.1B (-$8.74B)

Holders
878
Holders Change
-26
Holders Change %
-2.88%
% of All Funds
14.79%
Holding in Top 10
21
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+50%
% of All Funds
0.35%
New
80
Increased
326
Reduced
320
Closed
92
Calls
$312M
Puts
$313M
Net Calls
-$567K
Net Calls Change
+$48.3M
Name Holding Trade Value Shares
Change
Change in
Stake
MML Investors Services
376
MML Investors Services
Massachusetts
$1.52M +$227K +5,581 +16%
OAM
377
Oppenheimer Asset Management
New York
$1.5M -$35.2K -864 -2%
SG Americas Securities
378
SG Americas Securities
New York
$1.47M -$153K -3,747 -9%
YC
379
Yarbrough Capital
Tennessee
$1.43M
RIM
380
Redpoint Investment Management
Australia
$1.42M +$102K +2,503 +7%
IAS
381
IMA Advisory Services
Colorado
$1.41M -$287K -7,056 -16%
Wealthfront Advisers
382
Wealthfront Advisers
California
$1.41M -$37.8K -929 -2%
Rockefeller Capital Management
383
Rockefeller Capital Management
New York
$1.38M +$220K +5,394 +17%
TI
384
Trexquant Investment
Connecticut
$1.38M +$1.5M +36,907 New
AP
385
Advisor Partners
California
$1.34M -$190K -4,677 -11%
AA
386
ALPS Advisors
Colorado
$1.34M -$405K -9,959 -22%
NSEDCP
387
NJ State Employees Deferred Compensation Plan
New Jersey
$1.34M
CCM
388
Conway Capital Management
California
$1.32M -$22.4K -550 -2%
MC
389
Moors & Cabot
Massachusetts
$1.32M +$122K +2,990 +9%
HighTower Advisors
390
HighTower Advisors
Illinois
$1.31M -$49.2K -1,208 -3%
FCM
391
Fairbanks Capital Management
California
$1.31M -$38.3K -940 -3%
Rafferty Asset Management
392
Rafferty Asset Management
New York
$1.29M -$361K -8,873 -20%
AII
393
AGF Investments Inc
Ontario, Canada
$1.28M +$38.5K +946 +3%
OF
394
Outfitter Financial
Maine
$1.27M +$4.07K +100 +0.3%
SAM
395
Shell Asset Management
Netherlands
$1.27M +$19.3K +474 +1%
RC
396
RegentAtlantic Capital
New Jersey
$1.26M +$11.5K +283 +0.8%
CAPTRUST Financial Advisors
397
CAPTRUST Financial Advisors
North Carolina
$1.25M +$241K +5,926 +22%
VI
398
Vestcor Inc
New Brunswick, Canada
$1.24M +$434K +10,662 +47%
Walleye Trading
399
Walleye Trading
New York
$1.21M -$421K -10,347 -24%
FB
400
Fulton Bank
Pennsylvania
$1.21M -$15.5K -380 -1%

BSX Hedge Fund Activity: Q2 2022 in Review

878 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q2 2022, worth a combined $48.1B — down 15% from $56.8B a quarter earlier.

Sellers outnumbered buyers: 92 funds closed out of BSX and 80 opened new positions — a net loss of 12 holders — while 320 trimmed existing stakes and 326 added.

The largest buyer was Ameriprise, adding an estimated $303M. The largest seller was Fidelity Investments, cutting an estimated $617M.

  • 878 institutional investors held Boston Scientific (BSX) as of Q2 2022, down from 904 in Q1 2022.
  • Funds reported $48.1B of Boston Scientific stock for Q2 2022, down 15% quarter-over-quarter.
  • 80 funds opened new Boston Scientific positions in Q2 2022 and 92 closed out, a net change of -12 holders.
  • The largest Boston Scientific buyer in Q2 2022 was Ameriprise, an estimated $303M added.
  • The largest Boston Scientific seller in Q2 2022 was Fidelity Investments, an estimated $617M sold.

Based on aggregated 13F filings for Q2 2022.